1 INTRODUCTION {#SEC1}
==============

In recent years, biological sciences have taken full advantage of rather inexpensive high-throughput technologies. New experiments at a systemic level have been conceived to dissect the role of genetic and environmental factors in the development of common diseases or the identification of risk factors for complex phenotypes ([@B4]). The dimensions and diversity of available genetic, genomics and other \'omics data sets pose new theoretical and computational problems requiring multi-level data integration and efficient statistical analysis tools.

When the aim is to predict the variation of pathophysiological or complex phenotypes, regression models are widely used. In this set up, Bayesian variable selection (BVS) allows the construction of parsimonious regression models for high-dimensional datasets, adopting prior specifications that translate expected sparsity of the underlying biology and facilitate the interpretation of the results. Moreover, in problems where no single model stands out, model uncertainty is taken into account, reporting competing models with their posterior evidence.

*ESS*++ is a C++ implementation of a fully BVS approach for linear regression that can analyse single and multiple responses in an integrated way ([@B2]; [@B5]). Whereas other approaches ([@B6]) consider one predictor at the time, *ESS*++ performs an efficient search for combinations of covariates that predict the variation of single and multiple responses. Like *Shotgun Stochastic Search* ([@B3]), *ESS*++ is also designed to work under the "large *p*, small *n*" paradigm i.e. when the number of predictors *p* is large with respect to the number of observations *n*, thus making fully Bayesian analysis feasible in genetics/genomics experiments.

When the number of predictors is large, the multimodality of the model space is a known issue in variable selection. *ESS*++ explores the 2^*p*^-dimensional model space using an extension of parallel tempering called Evolutionary Monte Carlo that combines Markov chain Monte Carlo (MCMC) and genetic algorithms. Specifically, *ESS*++ relies on running multiple tempered chains in parallel which exchange information about set of covariates that are selected in the regression models. Since chains with higher temperatures flatten the posterior density, global moves (between chains) allow the algorithm to jump from one local mode to another. Local moves (within-chains) permit the fine exploration of alternative models, resulting in a combined algorithm that ensures that the chains mix efficiently and do not become trapped in local modes.

2 EXAMPLES OF *ESS*++ APPLICATION {#SEC2}
=================================

In this section, we present the results of the application of *ESS*++ to investigate genetic regulation. To discover the genetic causes of variation in the expression (i.e. transcription) of genes, gene expression data are treated as a quantitative phenotype while genotype data (SNPs) are used as predictors, a type of analysis known as expression Quantitative Trait Loci (eQTL). In this context, it is important to distinguish *cis*-eQTLs, where the genetic control points (SNPs) are located close to the location of the transcribed gene, from *trans*-acting eQTLs, which lie on a different chromosome. Here, we use a larger dataset ([@B4]) to reanalyse three genes (*Cd36*, *Ascl3* and *Hopx*) that were presented in [@B5]): in particular, for each gene we investigate the ability of *ESS*++ to find a parsimonious set of predictors (polygenic regulation) that explain the joint variability of gene expression in seven tissues (adrenal gland, aorta, fat, heart, kidney, liver, skeletal muscle) using 1304 SNPs and 29 observations, taken from the rat inbred lines that were studied.

We run *ESS*++ for 2.2M sweeps with 200K as burn-in using four chains. The prior requires two main user-defined parameters the *a priori* expected model size and SD of the model size. We set these to *E*(*p*~γ~)=2 and *sd*(*p*~γ~)=2, respectively, meaning the prior model size is likely to range from 0 to 8.

For each gene, [Figure 1](#F1){ref-type="fig"} shows the marginal posterior probability of inclusion (MPPI), a measure of the marginal contribution of each predictor. For the first gene *Cd36*, [Figure 1](#F1){ref-type="fig"}a, *ESS*++ confirms shared genetic effects due to a single *cis*-eQTL (SNP *J664145*) and *in silico* prediction of its systemic effect in all tissues ([@B1]). For the second gene *Ascl3*, [Figure 1](#F1){ref-type="fig"}b, *ESS*++ also finds a single *cis*-acting genetic control point (SNP *J697407*) for the variation of the gene expression in all seven tissues, highlighting the fact that the second *trans*-acting locus found in [@B5]) was specific for the four tissues considered (adrenal gland, fat, heart, kidney). The landscape for the MPPI is much more complicated for the last gene *Hopx*, [Figure 1](#F1){ref-type="fig"}c, although the locus with highest MPPI (SNP *WKY-G-j-20h03~*f*~1_365*) is the one identified in [@B5]). Fig. 1.Marginal posterior probability of inclusion (MPPI) obtained running *ESS*++ on a multiple tissues mapping experiment for three different genes: for each gene, the set of SNPs associated with high MPPI (\>0.50) are highlighted, showing monogenic control for (**a**) *Cd36* gene (SNP *J664145*) and (**b**) *Ascl3* gene (SNP *J697407*), with evidence for polygenic control for (**c**) *Hopx* gene (SNP *WKY-G-j-20h03~*f*~1_365* and SNP *J590621*).

One of the distinctive features of *ESS*++ is also the possibility to look at the best models visited during the MCMC run. For instance, in the *Hopx* gene the 10 best visited models are all polygenic, SNP *WKY-G-j-20h03~*f*~1_365* is included in all 10 best visited models and altogether they account for about 15% of the posterior mass. Finally, when compared with the computational time of the Matlab implementation of [@B5]), *ESS*++ runs on a 3 GHz desktop computer, with the same MCMC specifications roughly 15 times faster (in 36, 74, and roughly 400 minutes for the examples above).

3 DOCUMENTATION AND IMPLEMENTATION {#SEC3}
==================================

*ESS*++ is written in C++. Documentation of the algorithm (provided with the code and in the Supplementary Material) details not only the installation on different platforms and the contents of the package, but also how to run *ESS*++.

The command line of *ESS*++ is extremely simple and it requires few specifications from the user: the response and predictor matrices (`-Y file_name`, `-X file_name`); the number of sweeps and the burn-in period (`-nsweep int`, `-burn_in int`); if an hyperprior on the regression coefficient is required (`-g_set`); if the user prefers a standard/detailed output for the summary statistics (`-out file_name`, `-out_full file_name`); and if additional output files (MCMC move histories) are required (`-history`).

The set-up of *ESS*++ is highly customizable by the user through the modification of the `-par` file. Among several other settings it is possible to define: the *a priori* expected value and the SD of the number of predictors (`E_P_GAM`, `SD_P_GAM`); the number of chains and their initial distance (`NB_CHAINS`, `B_T`); the parameters for the evolutionary part of the algorithm such as the proportion of local and global moves (`P_MUTATION`); and the weighting of different types of global moves (`P_DR`). We refer the reader to Table 1 of the accompanying documentation for full details on all the parameters that can be entered in *ESS*++.

The C++ implementation of *ESS*++ is open source. Its natural object-oriented structure favours community-based alterations and improvements. *ESS*++ is memory efficient and can be run, even for very large datasets, on a desktop computer. However, when thousands of observations are collected, the calculation of the (marginal) likelihood, which relies on costly linear algebra operations (QR decomposition, matrix multiplication), becomes rate limiting. A future development for *ESS*++ will be the translation of some of these linear algebra operations into Compute Unified Device Architecture.
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